Once-weekly teriparatide improves glucocorticoid-induced osteoporosis in patients with inadequate response to bisphosphonates

BACKGROUND: Patients with glucocorticoid-induced osteoporosis (GIOP) are at very high risk of fracture, and patients with severe GIOP often experience fractures during treatment with bisphosphonates. Teriparatide (TPTD) is the only currently available anabolic agent expected to be effective for GIOP...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Springerplus
Päätekijät: Seno, Takahiro, Yamamoto, Aihiro, Kukida, Yuji, Hirano, Aiko, Kida, Takashi, Nakabayashi, Amane, Fujioka, Kazuki, Nagahara, Hidetake, Fujii, Wataru, Murakami, Ken, Oda, Ryo, Fujiwara, Hiroyoshi, Kohno, Masataka, Kawahito, Yutaka
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Springer International Publishing 2016
Aiheet:
Research
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4940355/
https://ncbi.nlm.nih.gov/pubmed/27462504
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40064-016-2704-5
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia